Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; referees

3 approved]

Igor S. Lukashevich, Slobodan Paessler, Juan Carlos de la Torre

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.

Original languageEnglish (US)
Article number134
JournalF1000Research
Volume8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lassa virus
Viruses
Vaccines
Lassa Fever
Murinae
Western Africa
Africa South of the Sahara
Biodiversity
Pathogens
Virus Diseases
United States Food and Drug Administration
Rodentia
Health
Morbidity
Mortality

Keywords

  • Lassa fever
  • Lassa virus
  • Vaccine development

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; referees : 3 approved]. / Lukashevich, Igor S.; Paessler, Slobodan; de la Torre, Juan Carlos.

In: F1000Research, Vol. 8, 134, 01.01.2019.

Research output: Contribution to journalReview article

@article{a2af35eece124b25b85b89596f335010,
title = "Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; referees: 3 approved]",
abstract = "Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.",
keywords = "Lassa fever, Lassa virus, Vaccine development",
author = "Lukashevich, {Igor S.} and Slobodan Paessler and {de la Torre}, {Juan Carlos}",
year = "2019",
month = "1",
day = "1",
doi = "10.12688/f1000research.16989.1",
language = "English (US)",
volume = "8",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; referees

T2 - 3 approved]

AU - Lukashevich, Igor S.

AU - Paessler, Slobodan

AU - de la Torre, Juan Carlos

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.

AB - Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.

KW - Lassa fever

KW - Lassa virus

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=85061113922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061113922&partnerID=8YFLogxK

U2 - 10.12688/f1000research.16989.1

DO - 10.12688/f1000research.16989.1

M3 - Review article

VL - 8

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 134

ER -